OPNT Opiant Pharmaceuticals Inc

LONDON, May 3, 2012 /PRNewswire/ -- Lightlake Therapeutics Inc. (OTCBB: LLTP) (the "Company" or "Lightlake"), an early stage biopharmaceutical company developing addiction treatments, announced today very encouraging preliminary results in the Phase II clinical trial of the Company's opioid antagonist nasal spray treatment for patients with Binge Eating Disorder (BED).  BED is a psychiatric condition that is manifested by recurrent episodes of eating unusually large amounts of food in a short period of time associated with a sense of lack of control.

Lightlake's randomised, double-blind, placebo-controlled, six month Phase II clinical trial enrolling 127 subjects in Helsinki for the treatment of binge eating disorder (BED) with intranasal naloxone has been completed successfully.  There were no serious adverse events and 81% of patients completed the entire 6 months with no statistically significant difference in dropout rates between the placebo and the treatment groups.

The primary endpoint was measured as the time (minutes) per week spent binge eating.  The group receiving naloxone showed a highly significant (p